Cargando…

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression

OBJECTIVE: To evaluate the influence of oral laquinimod, a candidate multiple sclerosis (MS) treatment, on induction of T follicular helper cells, development of meningeal B cell aggregates, and clinical disease in a spontaneous B cell–dependent MS model. METHODS: Experimental autoimmune encephalomy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varrin-Doyer, Michel, Pekarek, Kara L., Spencer, Collin M., Bernard, Claude C.A., Sobel, Raymond A., Cree, Bruce A.C., Schulze-Topphoff, Ulf, Zamvil, Scott S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032667/ https://www.ncbi.nlm.nih.gov/pubmed/27704036 http://dx.doi.org/10.1212/NXI.0000000000000272

Ejemplares similares

Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
por: Schulze-Topphoff, Ulf, et al.
Publicado: (2012)

Aquaporin 4-Specific T Cells in Neuromyelitis Optica Exhibit a Th17 Bias and Recognize Clostridium ABC Transporter
por: Varrin-Doyer, Michel, et al.
Publicado: (2012)

MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS
por: Varrin-Doyer, Michel, et al.
Publicado: (2014)

Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity
por: Schulze-Topphoff, Ulf, et al.
Publicado: (2013)

Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE
por: Shetty, Aparna, et al.
Publicado: (2014)

Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens
por: Cree, Bruce A. C., et al.
Publicado: (2016)

MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies
por: Molnarfi, Nicolas, et al.
Publicado: (2013)

Immunodominant T Cell Determinants of Aquaporin-4, the Autoantigen Associated with Neuromyelitis Optica
por: Nelson, Patricia A., et al.
Publicado: (2010)

Glatiramer acetate treatment negatively regulates type I interferon signaling
por: Molnarfi, Nicolas, et al.
Publicado: (2015)

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
por: Spencer, Collin M., et al.
Publicado: (2015)

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS
por: Harris, Sarah, et al.
Publicado: (2020)

Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea
por: Li, Zuohong, et al.
Publicado: (2020)

Laquinimod Supports Remyelination in Non-Supportive Environments
por: Nyamoya, Stella, et al.
Publicado: (2019)

CNS accumulation of regulatory B cells is VLA-4-dependent
por: Lehmann-Horn, Klaus, et al.
Publicado: (2016)

Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
por: Kolb-Sobieraj, Channa, et al.
Publicado: (2014)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

The Gut Microbiome in Neuromyelitis Optica
por: Zamvil, Scott S., et al.
Publicado: (2017)

Laquinimod in the treatment of multiple sclerosis: a review of the data so far
por: Thöne, Jan, et al.
Publicado: (2016)

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
por: Mishra, Manoj Kumar, et al.
Publicado: (2014)

Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
por: Gentile, Antonietta, et al.
Publicado: (2018)

Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model
por: Wilmes, Anna T., et al.
Publicado: (2018)

The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS
por: Rothhammer, Veit, et al.
Publicado: (2021)

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
por: Kramann, Nadine, et al.
Publicado: (2016)

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
por: Dobson, Lucianne, et al.
Publicado: (2016)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Regulators of Tfh Cell Differentiation
por: Jogdand, Gajendra M., et al.
Publicado: (2016)

TFH cells in systemic sclerosis
por: Beurier, Pauline, et al.
Publicado: (2021)

Transcriptomic Impact of IMA-08401, a Novel AHR Agonist Resembling Laquinimod, on Rat Liver
por: Prokopec, Stephenie D., et al.
Publicado: (2019)

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)

Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model
por: Katsumoto, Atsuko, et al.
Publicado: (2018)

Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
por: Colombo, Emanuela, et al.
Publicado: (2020)

B‐cell very late antigen‐4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity
por: Lehmann‐Horn, Klaus, et al.
Publicado: (2015)

Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS
por: Engel, Sinah, et al.
Publicado: (2020)

Circulating memory T follicular helper subsets, Tfh2 and Tfh17, participate in the pathogenesis of Guillain-Barré syndrome
por: Che, Yuanyuan, et al.
Publicado: (2016)

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
por: Brück, Wolfgang, et al.
Publicado: (2012)

Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis
por: Moore, Spencer, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2pbpr4eq1cism0sq7bn78bve92